All News

An 11-fold increase in geometric mean neutralizing antibody titers was reported at 2 weeks after the second booster compared to 5 months after the first booster dose.

The drug met the co-primary endpoints of clinical remission at both weeks 12 and 52 and all key secondary endpoints in the study.

Patient treatment improves and medication prices decline as a result, a new analysis indicates.

Pharmacy Times spoke with students at the Idaho State University College of Pharmacy and its partner program at the University of Alaska Anchorage College of Health.

Fourth-year student Ashley Lam discussed how pharmacists and pharmacy students can get involved in environmental issues.

Semaglutide (Ozempic; Novo Nordisk) approved as a once-weekly subcutaneous injection for the treatment of adults with type 2 diabetes.

FDA approves the EVO/EVO+ Visian Implantable Collamer Lens for the correction of myopia and myopia with astigmatism.

RBX2660, a standardized, stabilized, novel microbiota-based live therapeutic, shows promise treating patients with recurrent Clostridium difficile infection.

Ibalizumab-uiyk (Trogarzo) is a CD4-directed post-attachment HIV-1 inhibitor.

The monotherapy demonstrates rapidly improved symptoms over 4 weeks for individuals with moderate-to-severe disease.

Abemaciclib (Verzenio; Lilly) is the first addition to adjuvant endocrine therapy approved by the FDA in two decades.

Johnson & Johnson’s Janssen Pharmaceutical Companies subsidiary’s post-hoc analysis of Tremfya demonstrates clinically significant improvements.

Study finds that the use of biologics and other potentially immunocompromising therapies for atopic dermatitis was associated with low risk of severe COVID-19.

Access to buprenorphine among Medicaid beneficiaries was not affected during the pandemic.

Prurigo nodularis causes intense, persistent itch, with thick skin nodules that can cover most of the body.

Curtailing the availability of meth precursors in the principal focus of the law, paving the way for states to follow suit.

Patients in the atogepant 60 mg daily and 30 mg twice daily treatment arms of the study experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively.

Baricitinib (Olumiant; Eli Lilly and Incyte ) was found to produce significant hair regrowth on the scalp, eyelashes, and eyebrows of adults with severe alopecia areata.

Electronic, open loop, clinical decision support system helped to produce a 38% lower overall mortality rate among patients with pneumonia.

Trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant) is a HER2/neu receptor antagonist indicated for early and advanced breast cancer, advanced stomach cancer, and gastroesophageal junction cancer.

Theraworx is a foam that offers relief from muscle cramps and spasm.

Acalabrutinib (Calquence; AstraZeneca) provides efficacy while maintaining favorable tolerability for patients with chronic lymphocytic leukemia.

FDA seeks to reduce diversion of pharmaceutical products via sales by unlicensed distributers and tighten up the supply chain by vetting trading partners.

Students from the University of the Sciences Philadelphia College of Pharmacy and the Rutgers University Ernest Mario School of Pharmacy went head-to-head to answer questions about the pharmacy field.

Heat waves, which are on the rise, appear to pose particular cardiovascular risk for Black populations and men, new study results show.

In proposed changes, the practice would fall within nonsterile compounding.

FDA approves label update for Cabenuva that makes the therapy’s oral lead-in with cabotegravir and rilpivirine tablets optional.